In this week’s VJOncology podcast, we are focusing again on Prostate Cancer Awareness Month, where we have collaborated with experts on liquid biopsies for tracking and predicting treatment outcomes in metastatic castration-resistant prostate cancer.

Join Chinmay Jani from the Sylvester Comprehensive Cancer Centre, Xin Gao from Massachusetts General Hospital Cancer Center, Christos Kyriakopoulos from the University of Wisconsin, Andrew Armstrong from the Duke Cancer Institute, and Susan Halabi from Duke University Medical Center, as they present various trial updates and their exclusive insights from this burgeoning field.

The post Prostate cancer awareness month: advances in liquid biopsies appeared first on VJOncology.

In this weeks VJOncology podcast, we explore key update from BTOG 2025 in thoracic oncology.

Prof. Sanjay Popat discusses the evolving role of ADCs in lung cancer treatment, focusing on efficacy, toxicity management, and biomarker integration. Prof. Samreen Ahmed examines ADC resistance mechanisms, drawing insights from breast cancer therapy to refine drug development strategies. Prof. Robert Rintoul reviews a new UK Lung Cancer Coalition report on genomic testing challenges and strategic solutions for faster diagnostics. Dr Adam Januszewski highlights the complexities of implementing genomics in the UK and the need for a streamlined approach. Prof. Neal Nivani concludes by reflecting on BTOG 2025’s success and NHS England’s new service specification.

The post BTOG 2025 Highlights appeared first on VJOncology.

In this weeks VJOncology podcast, three oncology experts delve into the transformative potential of liquid biopsy in breast cancer treatment.

First, Michail Ignatiadis (Jules Bordet Institute, Brussels, Belgium) discusses the clinical applications and challenges of utilizing liquid biopsy in metastatic breast cancer, focusing on the Phase III TREAT ctDNA trial (NCT05512364) and its implications for ER-positive, HER2-negative cases. Next, Marina Sharifi (University of Wisconsin Carbone Cancer Center, Madison, WI) introduces an innovative fragmentomic analysis of circulating tumor DNA (ct-DNA) to discern ER status in metastatic breast cancer, potentially minimizing the need for invasive tissue biopsies. Finally, Guilherme Nader-Marta (Dana-Farber Cancer Center, Boston, MA) shares insights from the PACE trial (NCT03147287), highlighting two pivotal studies that explore biomarkers in ER-positive, HER2-negative metastatic breast cancer and underscore the prognostic value of liquid biopsy in optimizing treatment strategies.

For more updates on breast cancer, be sure to visit our dedicated Breast Cancer Channel.

The post Liquid biopsy in breast cancer appeared first on VJOncology.

In this podcast, we will discuss recent developments in radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment, as part one of our series for Prostate Cancer Awareness Month. Listen to leading experts as they share breakthroughs in mCRPC research.

First, Omid Yazdanpanah, MD, from the University of California, shares findings from the VISION trial, which assessed 177Lu-PSMA-617 with or without androgen receptor pathway inhibitors (ARPIs) in patients with mCRPC, as well as the potential of radioligands with ARPIs in in the ENZA-p trial. Andrei Gafita, MD, from Johns Hopkins Medicine, subsequently discusses the significance of post-therapy LuPSMA-SPECT/CT in patients with mCRPC and Umang Swami, MD, MS, from the University of Utah, gives an overview of findings from the PRO-XL trial. Michael Morris, from Memorial Sloan Kettering Cancer Center, ends the podcast by addressing the challenges in using radioligand therapy for patients with mCRPC.

The post Prostate cancer awareness month: developments in radioligand therapy appeared first on VJOncology.

Join us in this episode as we go through the latest advancements in genitourinary cancer treatment presented at ASCO GU 2025 in San Francisco. Our expert guests provide insights into ground-breaking trials and studies that are reshaping the landscape of cancer therapy.

Join Nadine Houede, Xinan Sheng, Nicholas James, and Wenxin Xu, as they discuss highly anticipated updates such as results of neoadjuvant durvalumab with chemotherapy in high-risk high-risk upper tract urothelial carcinoma (UTUC), disitamab vedotin and toripalimab in HER2-expressing bladder cancer, and updates from the STAMPEDE trial.

The post Key updates at ASCO GU 2025: STAMPEDE, CheckMate 214, and more appeared first on VJOncology.

Welcome to this week’s podcast by VJOncology, where we delve into the emerging trends and challenges in the field of cellular therapies for oncology. Our expert panel includes Leonardo Ferreira (The Medical University of South Carolina, Charleston, SC), who discusses the groundbreaking potential and current obstacles of CAR T cells in treating solid tumors, emphasizing the innovative role of chimeric antigen receptor regulatory T cells.

We also hear from Sebastian Klobuch (Netherlands Cancer Institute, Amsterdam, The Netherlands) on the advancements in TIL and TCR-modified therapies. He explores potential ways to mitigate treatment toxicities and expand the applicability of these therapies beyond melanoma.

Andrew Furness (Royal Marsden Hospital, London, UK) highlights the promise of TIL therapy for melanoma, while addressing regulatory challenges. Allison Betof Warner (Stanford Cancer Center, Stanford, CA) provides insights into the evolving use of life looser in managing melanoma cases with brain metastases, alongside a specially designed pilot trial to explore treatment safety.

Mina Lobbous (Case Western Reserve University, Cleveland, OH) shares updates on gene-modified gamma-delta T cells targeting glioblastoma multiforme, focusing on phase one trial outcomes and future directions for improving patient survival rates.

The post Cellular therapies in solid tumors appeared first on VJOncology.

In this podcast, we explore the latest advancements in the treatment of PD-1 refractory melanoma. This week, we are joined by Allison Betof Warner (Stanford Cancer Center, Stanford, CA) and Omid Hamid (The Angeles Clinic and Research Institute, Los Angeles, CA) and Inderjit Mehmi (The Angeles Clinic and Research Institute, Los Angeles, CA).

We will hear about the clinical definitions and significance of PD-1 resistance, including insights from SITC on primary and secondary resistance. The discussion will also highlight the implications for clinical trial design and strategies to overcome resistance in melanoma therapy. Updates on emerging treatment options, including the combination of immunotherapies, promising data from trials involving tumor-infiltrating lymphocytes (TIL) and oncolytic viruses, and recent FDA approvals that are shaping new treatment paradigms, are also discussed. Additionally, future directions in melanoma research, such as engineered T cells and other cellular therapies, and their potential to improve patient outcomes.

For more updates on melanoma and skin cancer research, be sure to visit our dedicated Skin Cancer Channel.

The post Therapeutic options for PD1 refractory skin cancer appeared first on VJOncology.

In this week’s podcast, we will provide updates the emerging roles of circulating tumor DNA (ctDNA) in managing colorectal cancer. We are joined by Michael Brian LaPelusa, MD, University of Texas MD Anderson Cancer Center, Houston, TX; Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina; Anup Kasi, MD, MPH, University of Kansas Cancer Center, Kansas City, KS; Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; and Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.

The role of ctDNA in predicting treatment responses and assessing minimal residual disease (MRD) will be discussed. Biomarker-driven treatment strategies assessed in the TACT-D, and CAPRI 2-GOIM trials will additionally be evaluated in this week’s podcast.

The post Evaluating the Clinical Applications of ctDNA in Colorectal Cancer appeared first on VJOncology.

In this week’s podcast, we will discuss the most recent developments in breast cancer from the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. Join us as renowned experts exclusively speak with us on anticipated findings from clinical trials across different breast cancer subtypes.

Gaia Griguolo from University of Padova in Italy, first discusses the PATINA trial, which investigated the addition of palbociclib to anti-HER2 and endocrine therapy in HR+/HER2+ breast cancer and Puneet Singh from The University of Texas MD Anderson Cancer Center comments on the COMET trial, which compared active monitoring with surgical management in low-risk ductal carcinoma in situ (DCIS). Elisa Agostinetto from Jules Bordet Institute subsequently gives an overview of findings from the Phase II DECRESCENDO trial of anthracycline-free treatment for HER2-positive, HR-negative, node-negative early breast cancer. Icro Meattini closes this episode with results from the EUROPA and FAST-Forward studies.

The post Breast Cancer Updates from SABCS 2024 appeared first on VJOncology.

This week’s podcast from VJOncology brings you the latest updates on novel checkpoint inhibitors that target LAG-3, TIGIT, and TIM3 in solid tumors. Our panel of experts share the latest findings from their clinical trials that tested the efficacy of different immune checkpoint inhibitors in neoplastic tumors.

Myriam Chalabi from the Netherlands Cancer Institute shares results from the NICHE-2 and NICHE-3 trials on MMR-deficient colon cancer, and Girish Kulkarni from the University of Toronto discusses the cohort C section of the KEYNOTE-057 trial, followed by the potential role of TIGIT/LAG-3 inhibition for urothelial carcinoma treatment. Ghassan Abou-Alfa from the Memorial Sloan Kettering Cancer Center shares results from different trials on anti-TIGIT therapies in hepatocellular carcinoma. Diwakar Davar from the University of Pittsburgh School of Medicine concludes with main findings from the AMBER trial on cobolimab for the treatment of non-small cell lung cancer.

The post Novel immune checkpoint targets beyond PD-1 and CTLA-4 in solid tumors appeared first on VJOncology.